Brief: Akebia Therapeutics And U.S. Renal Care Initiate The Voice Trial Of Vafseo (Vadadustat) For Patients On Dialysis
05/09/2024 13:42
Sept 5 (Reuters) - Akebia Therapeutics Inc AKBA.O :
* AKEBIA THERAPEUTICS AND U.S. RENAL CARE INITIATE THE VOICE
TRIAL
OF VAFSEO® (VADADUSTAT) FOR PATIENTS ON DIALYSIS
Source text for Eikon: ID:nPn12bFYHa
Further company coverage: AKBA.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule